streptomycin

Streptomycin sulfate (Phytomycin) 是一种能抑制蛋白质合成的氨基糖苷类抗生素。

Kanamycin sulfate (Kanamycin monosulfate) 属于氨基糖苷类抗生素，通过与细菌 70S 核糖体亚基结合来干扰蛋白质合成。Kanamycin sulfate 具有抗菌活性，对革兰氏阳性菌和阴性菌及支原体都有抑制作用。

Streptomycin (Agrept) 是一种可从链霉菌中分离得到的氨基糖苷类抗生素，是神经元和心肌细胞中拉伸激活和机械敏感离子通道的阻滞剂，具有抗结核活性，可与核酸强结合，干扰和阻断蛋白质合成，可用于研究结核杆菌感染。

Hydroxystreptomycin is a new antibiotic isolated from Streptomyces Griseocarneus.

Streptomycin BSA 是 Streptomycin与牛血清白蛋白 (BSA) 的抗原-佐剂缀合物。该缀合物通过将抗原与蛋白佐剂结合，能够增强疫苗模型中的抗原特异性抗体生成，同时不会影响蛋白质的折叠或破坏主要表位，还可增强交叉呈递和抗原特异性 T 细胞的产生。

Streptomycin KLH 是一种由 Streptomycin 和血蓝蛋白 (KLH) 缀合而成的抗原-佐剂偶联物。通过将抗原与蛋白佐剂结合，这种缀合物可以在疫苗模型中促进抗原特异性抗体的生成。它不会改变蛋白质的折叠结构或破坏主要表位，还能增强交叉呈递以及抗原特异性 T 细胞的产生。

Streptomycin OVA 是一种由 Streptomycin 和鸡卵白蛋白 (OVA) 缀合而成的抗原-佐剂偶联物。将抗原与蛋白质佐剂结合，可以在疫苗模型中提高抗原特异性抗体的产生。此缀合物不会干扰蛋白质折叠或损害主要表位，并能增强交叉呈递及抗原特异性 T 细胞的生成。

Dihydrostreptomycin sulfate (Dihydrostreptomycin sesquisulfate) 是一种氨基糖苷类抗生素，可研究牛、猪和羊的细菌性疾病。

Dihydrostreptomycin is an antibiotic.

Streptoniazid是一种链霉素的衍生物，是一种对抗结核病有效的抗生素。

Streptomyces A-Factor is a microbial hormone found in Streptomyces griseus. A-factor triggers streptomycin biosynthesis and cell differentiation by binding a repressor-type receptor protein (ArpA) and dissociating it from DNA.

Streptobiosamine is a disaccharide component of streptomycin.

OPC-167832 is a potent and orally active dprE1 Inhibitor with an IC50 of 0.258 μM. OPC-167832 has antituberculosis activity and can be used for the research of tuberculosis caused by Mycobacterium tuberculosis[1]. OPC-167832 exhibits very low MICs against laboratory strains of M. tuberculosis H37Rv (MIC: 0.0005 μg ml) and Kurono (MIC: 0.0005 μg ml) and strains with monoresistance to rifampin (RIF), isoniazid (INH), ethambutol (EMB), streptomycin (STR), and pyrazinamide (PZA) (MIC: 0.00024-0.001 μg ml). However, OPC-167832 has minimal or no activity against standard strains of nonmycobacterial aerobic and anaerobic bacteria[1].The IC90 values of OPC-167832 against intracellular M. tuberculosis strains H37Rv and Kurono are 0.0048 and 0.0027 μg ml, respectively. OPC-167832 shows bactericidal activity against intracellular M. tuberculosis at a low concentration, and the bactericidal activity is saturated at concentrations of 0.004 μg ml or higher[1]. OPC-167832 (oral administration; 0.625-10 mg kg) exhibits a good pharmacokinetic characteristic. The plasma reaches peak at 0.5 h to 1.0 h (tmax) and is eliminated with a half-life (t1 2) of 1.3 h to 2.1 h OPC-167832 distribution in the lungs is approximately 2 times higher than that in plasma, and the Cmax and AUCt of OPC-167832 in plasma and the lungs shows dose dependency[1].OPC-167832 (oral administration; 0.625-10 mg kg; 4 weeks) significantly reduces lung CFU compared to the vehicle group. The dose-dependent decrease of lung CFU is observed from 0.625 mg kg to 2.5 mg kg. In a M. tuberculosis Kurono-infected ICR female mice model. OPC-167832 combines with DMD, BDQ, or LVX via oral gavage exhibits significantly higher efficacies than each single agent alone[1].[1].OPC-167832 (oral gavage; 2.5 mg kg; combination with DCMB; 12 weeks) demonstrates the most potent efficacy when compares with DC, DCB. The lung CFU count after 6 weeks of treatment is below the detection limit, and at the end of just 8 weeks of treatment, the bacteria in the lungs of all the evaluated mice had already been eradicate[1]. [1]. Norimitsu Hariguchi, et al. OPC-167832, a Novel Carbostyril Derivative with Potent Antituberculosis Activity as a DprE1 Inhibitor.Antimicrob Agents Chemother. 2020 May 21;64(6):e02020-19.

Ashimycin B 是一种与Streptomycin类似的化合物，具有广泛的抗菌活性。

Ashimycin A 是一种与Streptomycin相似的化合物，具备广泛的抗菌性能。